Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report […]
Jefferies Financial Group restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a report released on Monday, Benzinga reports. Jefferies Financial Group currently has a $25.60 price target on the stock, down from their prior price target of $26.00. DCPH has been the topic of several other research reports. Jonestrading […]
Jonestrading restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Jonestrading currently has a $25.60 price objective on the stock. Several other research firms also recently weighed in on DCPH. JPMorgan Chase & Co. lifted their target price on […]
Jonestrading restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $25.60 price objective on the stock. Several other research analysts also recently issued reports on DCPH. Stifel Nicolaus raised their price objective on shares of Deciphera Pharmaceuticals from […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,116,913 shares changed hands during mid-day trading, a decline of 1% from the previous session’s volume of 1,129,558 shares.The stock last traded at $25.30 and had previously closed at $25.28. Analyst Ratings Changes Several research firms have […]